Chandler Paulette D, Giovannucci Edward L, Scott Jamil B, Bennett Gary G, Ng Kimmie, Chan Andrew T, Hollis Bruce W, Emmons Karen M, Fuchs Charles S, Drake Bettina F
Division of Preventive Medicine, Brigham and Women's Hospital, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts. Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts. Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts. Department of Epidemiology and Biostatistics, College of Human Medicine, Michigan State University, East Lansing, Michigan.
Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1944-7. doi: 10.1158/1055-9965.EPI-14-0522. Epub 2014 Jun 28.
Black men exhibit a high prevalence of vitamin D deficiency as well as a higher incidence of prostate cancer and higher mortality rates from prostate cancer than Whites. There are few data about the effect of vitamin D3 (cholecalciferol) supplementation on prostate-specific antigen (PSA) in healthy Black men.
During three winters from 2007 to 2010, 105 Black men (median age, 48.9 years) of Boston, MA were randomized into a four-arm, double-blind trial for 3 months of placebo, 1,000, 2,000, or 4,000 U of vitamin D3. At baseline and 3 months, free and total PSA was measured.
With vitamin D supplementation, no significant differences in free and total PSA were observed; free PSA, -0.0004 ng/mL (P = 0.94) and total PSA, -0.004 ng/mL (P = 0.92) for each additional 1,000 U/d of vitamin D3.
Within an unselected population of healthy Black men without a cancer diagnosis, we found no effect of vitamin D supplementation on free or total PSA.
These findings support prior findings of no change in PSA with vitamin D supplementation and emphasize the need for new methods to assess the influence of vitamin D supplementation on prostate cancer prevention.
黑人男性维生素D缺乏的患病率较高，前列腺癌的发病率和死亡率也高于白人。关于补充维生素D3（胆钙化醇）对健康黑人男性前列腺特异性抗原（PSA）的影响，相关数据较少。
在2007年至2010年的三个冬季，马萨诸塞州波士顿的105名黑人男性（中位年龄48.9岁）被随机分为四组，进行为期3个月的双盲试验，分别服用安慰剂、1000、2000或4000单位的维生素D3。在基线和3个月时，测量游离和总PSA。
补充维生素D后，游离和总PSA未观察到显著差异；每增加1000单位/天的维生素D3，游离PSA为-0.0004纳克/毫升（P = 0.94），总PSA为-0.004纳克/毫升（P = 0.92）。
在未选择的无癌症诊断的健康黑人男性人群中，我们发现补充维生素D对游离或总PSA没有影响。
这些发现支持了先前关于补充维生素D后PSA无变化的研究结果，并强调需要新的方法来评估补充维生素D对前列腺癌预防的影响。
